BioCentury
ARTICLE | Company News

Germany again rebuffs Trajenta

December 4, 2012 3:41 AM UTC

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) reassessed Trajenta linagliptin from Boehringer Ingelheim GmbH (Ingelheim, Germany) and said the diabetes drug provides "no additional benefit" over sulfonylurea, a comparator requested by Germany's Federal Joint Committee (G-BA). Boehringer said it sees a "clear additional benefit" for the dipeptidyl peptidase-4 (DPP-4) inhibitor and will submit a response to G-BA by Dec. 24. A final benefit assessment from G-BA is expected in late February 2013.

In March, G-BA issued an unfavorable benefit assessment for Trajenta after Boehringer compared its drug with Januvia sitagliptin, a DDP-4 inhibitor from Merck & Co. Inc. (NYSE:MRK). At the time, G-BA said Trajenta should be compared with a sulfonylurea (see BioCentury Extra, Sept. 4). ...